Search Grant Opportunities

Phased Multi-Site Clinical Trial: Testing Prevention of Cardiovascular Disease in Young Adults With High Lifetime Risk Using Surrogate Outcomes - Clinical Coordinating Center (Collaborative UG3/UH3 Clinical Trial Required)

ID: RFA-HL-25-010 • Type: Posted
Opportunity Assistant

Hello! Please let me know your questions about this opportunity. I will answer based on the available opportunity documents.

Sign in to upload a capability statement or catalogue for your company

Some suggestions:
Please summarize the work to be completed under this opportunity
Who is eligible to apply for this grant?
I'd like to anonymously submit a question to the procurement officer(s)
Loading

Description

Posted: July 10, 2024, 12:00 a.m. EDT
The goal of this funding opportunity for a Clinical Coordinating Center is to support a clinical trial which will test intervention(s) to reduce the progression of coronary atherosclerosis among young adults under the age of fifty years old who are at low or borderline 10-year risk ( 7.5%) for their first an atherosclerotic cardiovascular disease (ASCVD) event, yet at high lifetime risk of developing cardiovascular disease (CVD). This opportunity will support a two-phased primary prevention clinical trial that will first efficiently screen the appropriate population eligible for the intervention and second determine which intervention(s) are most efficacious at reducing the onset or slowing the progression of subclinical coronary atherosclerosis. It is expected that phase one will overlap with phase two. Trial participants who are identified as meeting the subclinical coronary atherosclerosis criteria for enrollment in the screening stage will be immediately enrolled in stage two even although stage one recruitment will continue until the trial is completely enrolled. It is expected that the trial will have three arms. One will be a control or comparison arm and the second and the third arm will test different interventions than the control arm. The control arm should be current guideline based behavioral interventions. One of the two non-control arms is expected to involvement pharmacological intervention(s) with definite evidence of efficacious for primary prevention in older high risk adults such as LDL- lowering therapy and the other arm may involve intervention(s) with less definite evidence of primary prevention efficacy in older adults The long range goal of this research strategy is to determine if earlier treatment prevents more CVD than current guideline recommended treatment. Applications for both a CCC and a DCC must be submitted on the same application due date for consideration by NHLBI.
Posted: Feb. 22, 2024, 12:00 a.m. EST
Posted: Feb. 22, 2024, 12:00 a.m. EST
Background
The goal of this funding opportunity is to support a clinical trial testing intervention(s) to reduce the progression of coronary atherosclerosis among young adults who are at low or borderline 10-year risk for their first atherosclerotic cardiovascular disease (ASCVD) event, yet at high lifetime risk of developing cardiovascular disease (CVD). The trial will have three arms, including a control or comparison arm and two active arms testing different interventions. The long-range goal is to determine if earlier treatment prevents more CVD than current guideline-recommended treatment.

Grant Details
The Clinical Coordinating Center (CCC) application should present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results for each stage and phase. The application should also describe approaches to increasing community engagement and reducing health inequities. The trial will have two phases: a two-year UG3 phase and a five-year UH3 phase. Milestones must be performance-based to achieve completion of the trial on time and on budget.

Eligibility Requirements
Eligible applicants include higher education institutions, nonprofits with 501(c)(3) IRS status (other than institutions of higher education), for-profit organizations (including small businesses), state governments, county governments, city or township governments, special district governments, independent school districts, public housing authorities/Indian housing authorities, Native American tribal organizations (other than federally recognized tribal governments), faith-based or community-based organizations. Foreign organizations are not eligible to apply.

Period of Performance
The maximum period of the combined UG3 and UH3 phases is 7 years, with up to 2 years for the UG3 phase and up to 5 years for the UH3 phase.

Overview

Category of Funding
Health
Funding Instruments
Cooperative Agreement
Grant Category
Discretionary
Cost Sharing / Matching Requirement
False
Source
On 7/10/24 the National Institutes of Health posted grant opportunity RFA-HL-25-010 for Phased Multi-Site Clinical Trial: Testing Prevention of Cardiovascular Disease in Young Adults With High Lifetime Risk Using Surrogate Outcomes - Clinical Coordinating Center (Collaborative UG3/UH3 Clinical Trial Required). The grant will be issued under grant program 93.837 Cardiovascular Diseases Research.

Timing

Posted Date
July 10, 2024, 12:00 a.m. EDT
Closing Date
Oct. 28, 2024, 12:00 a.m. EDT Past Due
Last Updated
July 10, 2024, 9:08 a.m. EDT
Version
1
Archive Date
Dec. 3, 2024

Eligibility

Eligible Applicants
State governments
Special district governments
Native American tribal organizations (other than Federally recognized tribal governments)
Public housing authorities/Indian housing authorities
Others (see text field entitled "Additional Information on Eligibility" for clarification)
County governments
City or township governments
Private institutions of higher education
For profit organizations other than small businesses
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Independent school districts
Public and State controlled institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Native American tribal governments (Federally recognized)
Small businesses
Additional Info
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

Contacts

Contact
National Institutes of Health
Contact Email
Email Description
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Contact Phone
(301) 402-2541
Additional Information
https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-25-010.html

Documents

Posted documents for RFA-HL-25-010

Grant Awards

Grants awarded through RFA-HL-25-010

Incumbent or Similar Grants

Grants similar to RFA-HL-25-010

Similar Active Opportunities

Open grant opportunities similar to RFA-HL-25-010

Experts for Phased Multi-Site Clinical Trial: Testing Prevention of Cardiovascular Disease in Young Adults With High Lifetime Risk Using Surrogate Outcomes - Clinical Coordinating Center (Collaborative UG3/UH3 Clinical Trial Required)

Recommended subject matter experts available for hire